Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302054 · ClinicalTrials.gov registry record · Phase 4
A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 990
- Enrollment target
NCT01302054 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 990 participants.
The verdict
NCT01302054, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 990 participants
- Enrollment target
Study Summary
Patients with overactive bladder are often treated with tolterodine, a medication that helps relax the bladder, helping symptoms of urinary incontinence and urinary frequency. Sometimes patients do not have a satisfactory response, and may benefit from trying an alternative oral medicine. Fesoterodine is related to tolterodine by producing the same active substance that acts on the bladder, but potentially at higher and more effective levels. So, a patient who has a poor response to tolterodine may still obtain a good response to fesoterodine. This study will help find out if this is what happens.
Interventions
- DRUG Placebo
- DRUG Fesoterodine 8 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 990 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302054
The ClinicalTrials.gov registry entry for NCT01302054 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 990 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01302054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01302054 about?
NCT01302054 is a clinical study titled "A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.". Patients with overactive bladder are often treated with tolterodine, a medication that helps relax the bladder, helping symptoms of urinary incontinence and urinary frequency. Sometimes patients do not have a satisfactory response, and may benefit from trying an alternative oral medicine. Fesoterodi...
What is the current status of trial NCT01302054?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 990 participants. The study started on 2011-05. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01302054?
The interventions under investigation include: Placebo (DRUG), Fesoterodine 8 mg (DRUG).
Who is sponsoring clinical trial NCT01302054?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.